Abstract
Because disease activity in systemic lupus erythematosus correlates well with increased serum levels and activity of the cytokine tumor necrosis factor alpha (TNF-α), we report on the safety and efficacy of infliximab, a chimeric monoclonal antibody directed against TNF-α, given to a patient with active lupus with diffuse proliferative nephritis (WHO Class IV). This patient who failed to remit with a combination of full-dose steroids, mycophenolate mofetil, and cyclosporine, went into sustained remission with the addition of infliximab infusions.
This is a preview of subscription content, log in via an institution to check access.
References
Hellmann DB (1991) Medical therapy for SLE. Md Med J 40(10):923–933 Oct
Robak E, Sysa-Jedrzejowska A, Robak T (1996) Cytokines in systemic lupus erythematosus. Przegl Lek 53(8):623–626
Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnowski K, Robak T (1998) Association of interferon gamma, tumor necrosis factor alpha and interleukin 6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp (Warsz) 46(6):375–380
Gilboe IM, Kvien TK, Husby G (2001) Disease course in systemic lupus erythematosus: changes in health status, disease activity, and organ damage after 2 years. J Rheumatol 28(2):266–274 (Feb)
Waszczykowska E, Robak E, Wozniacka A, Narbutt J, Torzecka JD, Sysa-Jedrzejowska A (1999) Estimation of SLE activity based on the serum level of chosen cytokines and superoxide radical generation. Mediators Inflamm 8(2):93–100
Prokop’ev AA, Alekseeva TG, Zimina ZV, Ketlinskii SA (1993) The level of the tumor necrosis factor in the blood serum of patients with systemic lupus erythematosus and rheumatoid arthritis. Ter Arkh 65:9–12
Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC (1999) Serum IL-6, TNFalpha, p55 srTNFalpha, p75srTNFalpha, srIL-2alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 18(1):17–22
Studnicka-Benke A, Steiner G, Petera P, Smolen JS (1996) Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 35(11):1067–1074 (Nov)
Aten J, Roos A, Claessen N, Schilder-Tol EJ, Ten BI, Weening JJ (2000) Strong and selective glomerular localization of CD134 ligand and TNF receptor-1 in proliferative lupus nephritis. J Am Soc Nephrol 11(8):1426–1438 (Aug)
Louis M, Rauch J, Armstrong M, Fitzcharles MA (2003) Induction of autoantibodies during prolonged treatment with infliximab. J Rheumatol 30(12):2557–2562 (Dec)
Charles PJ, Smeenk RJ, De JJ, Feldmann M, Maini RN (2000) Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 43(11):2383–2390 (Nov)
Pisetsky DS (2000) Tumor necrosis factor alpha blockers and the induction of anti-DNA autoantibodies. Arthritis Rheum 43(11):2381–2382 (Nov)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hayat, S.J., Uppal, S.S., Narayanan Nampoory, M.R. et al. Safety and efficacy of infliximab in a patient with active WHO class IV lupus nephritis. Clin Rheumatol 26, 973–975 (2007). https://doi.org/10.1007/s10067-006-0219-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-006-0219-0